BRIEF-Santarus up in premarket after FDA ok's ulcerative colitis dug
NEW YORK Jan 15 (Reuters) - Santarus Inc : * Up 8.6 percent premarket after FDA OK's its oral drug to treat a type of inflammatory bowel disease
- Exclusive: Secret contract tied NSA and security industry pioneer |
- U.S. aircraft hit by gunfire in South Sudan as conflict worsens
- With Fed out of the way, what's next on Wall Street?
- Analysis: Lost Brazil order raises threat to Boeing fighter jets
- Four men arrested in deadly N.J. shopping mall carjacking